8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:29 Page 122 122 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Other information Quarterly results of operations unaudited The following table presents summarized unaudited quarterly results for the years to December 31, 2010 and 2009: Q1 Q2 Q3 Q4 2010 $M $M $M $M Total revenues 816.2 849.4 874.3 931.2 Operating income 217.8 224.4 155.8 196.1 Net income attributable to Shire plc 165.9 160.5 96.3 165.3 Earnings per sharebasic 30.5 29.4 17.6 30.1 Earnings per sharediluted 29.7 28.6 17.3 29.4 Q1 Q2 Q3 Q4 2009 $M $M $M $M Total revenues 817.8 629.7 667.0 893.2 Operating income 225.8 34.7 91.8 267.8 Net income attributable to Shire plc 213.6 44.1 59.6 174.3 Earnings per sharebasic 39.6 8.2 11.0 32.1 Earnings per sharediluted 38.5 8.1 10.9 31.2 Non GAAP measures Divestments, re-organizations and discontinued operations Non GAAP financial measures are used by Shires management gains and losses on the sale of non-core assets: to make operating decisions because they facilitate comparisons costs associated with restructuring and re-organization activities: of Shires performance to historical results and to competitors results.
Shires Remuneration Committee uses certain key Non GAAPtermination costs: measures when assessing the performance and compensation costs associated with the introduction of the new holding of employees, including Shires Executive Directors.
company: and The Non GAAP measures are presented in this Annual Report as income losses from discontinued operations.
Shires management believe that they will provide investors with a means of evaluating, and an understanding of how Shires management Depreciation, which is included in Cost of product sales, Research evaluates, Shires performance and results on a comparable basis and development and Selling, general and administrative costs in our that is not otherwise apparent on a US GAAP basis, since many nonUS GAAP results, has been separately disclosed for the presentation recurring, infrequent or non-cash items that Shires management of 2008, 2009 and 2010 Non GAAP earnings.
believe are not indicative of the core performance of the business may not be excluded when preparing financial measures under US GAAP.
A reconciliation of Non GAAP financial measures to the most directly comparable measure under US GAAP is presented below.
These Non GAAP measures should not be considered in isolation from, as substitutes for, or superior to financial measures prepared Non GAAP EBITDA represents Non GAAP operating income before in accordance with US GAAP.
The following items, including their tax effect, have been excluded Non GAAP ROIC aims to measure true underlying economic from 2008, 2009 and 2010 Non GAAP earnings: performance of the Group, by making a number of adjustments to ROIC as derived from Shires Non GAAP financial results including: Amortization and asset impairments: Adding back to Non GAAP operating income all R&D expenses, intangible asset amortization and impairment charges: and intangible asset impairment charges and operating lease costs other-than-temporary impairment of investments.
incurred in the period: Capitalizing on the Groups balance sheet historic, cumulative R&D, Acquisitions and integration activities: IPR&D, intangible asset impairment charges and operating lease upfront payments and milestones in respect of in-licensed costs which previously have been expensed: and acquired products: Deducting from Non GAAP operating income an amortization charge costs associated with acquisitions, including transaction costs, for the above capitalized costs, based on the estimated commercial and fair value adjustments on contingent consideration and lives of the relevant products: acquired inventory: Excluding the income statement and balance sheet impact costs associated with the integration of companies: of non-operating assets such as surplus cash and non-strategic incremental interest charges arising on the settlement of litigation investments : and with the former dissenting shareholders of TKT: and Taxing the resulting adjusted operating income at the underlying Non GAAP tax rate.
noncontrolling interest in consolidated variable interest entities.
Other information 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:29 Page 123 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 123 Non GAAP reconciliation 2010 US GAAP Adjustments Non GAAP Divestments, Amortization Acquisitions re-organizations December 31, and asset and integration and discontinued Reclassify December 31, a b c d 2010 impairments activities operations depreciation 2010 Year to, $M $M $M $M $M $M Total revenues 3,471.1 3,471.1 Costs and expenses Cost of product sales 463.4 30.4 12.4 420.6 Research and development 661.5 45.0 19.0 597.5 Selling, general and administrative 1,526.3 176.2 62.1 1,288.0 Gain on sale of product rights 16.5 16.5 Re-organization costs 34.3 34.3 Integration and acquisition costs 8.0 8.0 Depreciation 93.5 93.5 Total operating expenses 2,677.0 176.2 53.0 48.2 2,399.6 Operating income 794.1 176.2 53.0 48.2 1,071.5 Interest income 2.4 2.4 Interest expense 35.1 35.1 Other income expense, net 7.9 11.1 3.2 Total other expense, net 24.8 11.1 35.9 Income from continuing operations before income taxes and equity in earnings of equity-method investees 769.3 176.2 53.0 37.1 1,035.6 Income taxes 182.7 38.9 3.5 13.5 238.6 Equity in earnings of equity-method investees, net of tax 1.4 1.4 Net income attributable to Shire plc 588.0 137.3 49.5 23.6 798.4 Impact of convertible debt, net of tax 33.5 33.5 Numerator for diluted EPS 621.5 137.3 49.5 23.6 831.9 Weighted-average number of shares millions diluted 590.3 590.3 Diluted earnings per ADS 315.9 69.7 25.1 12.0 422.7 The following items are included in Adjustments: a Amortization and asset impairments: Amortization of intangible assets relating to intellectual property rights acquired $133.5 million, impairment charge to record DAYTRANA assets at fair value less costs to sell $42.7 million and tax effect of adjustments: b Acquisitions and integration activities: Up-front payment to Acceleron $45.0 million, acquisition costs $8.0 million primarily related to the Movetis acquisition and tax effect of adjustments: c Divestments, re-organizations and discontinued operations: Accelerated depreciation $25.7 million and dual running costs $4.7 million on the transfer of manufacturing from Owings Mills to a third-party, gain on sale of non-core product rights $6.1 million, re-measurement of DAYTRANA contingent consideration to fair value $10.4 million, re-organization costs $34.3 million on the transfer of manufacturing from Owings Mills to a third-party and the establishment of an international commercial hub in Switzerland, gain on disposal of the investment in Virochem $11.1 million, and tax effect of adjustments: and d Depreciation: Depreciation of $93.5 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.
8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:29 Page 124 124 Shire plc Annual Report and Accounts 2010 Shire plc Annual Repo Other information Non GAAP reconciliation 2009 US GAAP Adjustments Non GAAP Divestments, Amortization Acquisitions re-organizations December 31, and asset and integration and discontinued Reclassify December 31, a b c d 2009 impairments activities operations depreciation 2009 Year to, $M $M $M $M $M $M Total revenues 3,007.7 3,007.7 Costs and expenses Cost of product sales 388.0 1.9 12.0 9.8 364.3 Research and development 638.3 36.9 62.9 15.5 523.0 Selling, general and administrative 1,342.6 136.9 67.7 1,138.0 Gain on sale of product rights 6.3 6.3 IPR&D 1.6 1.6 Re-organization costs 12.7 12.7 Integration and acquisition costs 10.6 10.6 Depreciation 93.0 93.0 Total operating expenses 2,387.5 136.9 51.0 81.3 2,118.3 Operating income 620.2 136.9 51.0 81.3 889.4 Interest income 1.9 1.9 Interest expense 39.8 39.8 Other income expense, net 60.7 55.2 5.5 Total other income expense, net 22.8 55.2 32.4 Income from continuing operations before income taxes and equity in losses of equity-method investees 643.0 136.9 51.0 26.1 857.0 Income taxes 138.5 38.8 16.2 20.7 214.2 Equity in losses of equity-method investees, net of tax 0.7 0.7 Income from continuing operations, net of tax 503.8 98.1 34.8 5.4 642.1 Loss from discontinued operations 12.4 12.4 Net income 491.4 98.1 34.8 17.8 642.1 Add: Net loss attributable to noncontrolling interest in subsidiaries 0.2 0.2 Net income attributable to Shire plc 491.6 98.1 34.8 17.8 642.3 1 Impact of convertible debt, net of tax 33.6 33.6 Numerator for diluted EPS 491.6 131.7 34.8 17.8 675.9 Weighted-average number of shares 1 millions diluted 548.0 33.1 581.1 Diluted earnings per ADS 269.1 52.6 18.0 9.2 348.9 1 The impact of convertible debt, net of tax has a dilutive effect on a Non GAAP basis.
The following items are included in Adjustments: a Amortization and asset impairments: Amortization of intangible assets relating to intellectual property rights acquired $136.9 million and tax effect of adjustment: b Acquisitions and integration activities: Inventory fair value adjustment related to the acquisition of Jerini $1.9 million : payment on amendment of INTUNIV in-license agreement $36.9 million : IPR&D charge in respect of Jerini $1.6 million, costs associated with the integration and acquisition of Jerini and EQUASYM $10.6 million : and tax effect of adjustments: c Divestments, re-organizations and discontinued operations: Accelerated depreciation $12.0 million and re-organization costs $12.7 million for the transition of manufacturing from Owings Mills to a third-party: costs associated with the agreement to terminate Womens Health products with Duramed $62.9 million : gain on disposal of non-core product rights $6.3 million : gain on disposal of investment in Virochem $55.2 million : discontinued operations in respect of non-core Jerini operations $12.4 million, and tax effect of adjustments: and d Depreciation: Depreciation of $93.0 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.
Other information 8100 Annual Report 2010 Annual Report 2010 15 03 2011 14:29 Page 125 ort and Accounts 2010 Shire plc Annual Report and Accounts 2010 125 Non GAAP reconciliation 2008 US GAAP Adjustments Non GAAP Divestments, Amortization Acquisitions re-organizations December 31, and asset and integration and discontinued Reclassify December 31, a b c d 2008 impairments activities operations depreciation 2008 Year to, $M $M $M $M $M $M Total revenues 3,022.2 3,022.2 Costs and expenses Cost of product sales 408.0 48.8 16.2 343.0 1 Research and development 494.3 6.5 12.5 475.3 1 Selling, general and administrative 1,455.2 223.3 14.8 48.5 1,168.6 Integration and acquisition costs 10.3 10.3 Gain on sale of product rights 20.7 20.7 IPR&D 263.1 263.1 Depreciation 77.2 77.2 Total operating expenses 2,610.2 223.3 273.4 49.4 2,064.1 Operating income 412.0 223.3 273.4 49.4 958.1 Interest income 25.5 25.5 Interest expense 139.0 73.0 66.0 Other expense income, net 32.9 58.0 9.4 15.7 Total other expense, net 146.4 58.0 73.0 9.4 24.8 Income from continuing operations before income taxes and equity in earnings of equity-method investees 265.6 281.3 346.4 40.0 933.3 Income taxes 98.0 39.1 60.9 12.4 210.4 Equity in earnings of equity-method investees, net of tax 2.4 2.4 Income from continuing operations, net of tax 170.0 242.2 285.5 27.6 725.3 Loss from discontinued operations 17.6 17.6 Net income 152.4 242.2 285.5 45.2 725.3 Add: Net loss attributable to noncontrolling interest in subsidiaries 3.6 3.6 Net income attributable to Shire plc 156.0 242.2 285.5 45.2 728.9 1 Impact of convertible debt, net of tax 14.6 14.6 Numerator for diluted EPS 156.0 256.8 285.5 45.2 743.5 Weighted-average number of shares 1 millions diluted 545.4 32.7 578.1 Diluted earnings per ADS 85.8 128.4 148.2 23.4 385.8 1 The impact of convertible debt, net of tax has a dilutive effect on a Non GAAP basis.
The following items are included in Adjustments: a Amortization and asset impairments: Amortization of intangible assets relating to intellectual property rights acquired $126.2 million, impairment charge in respect of DYNEPO intangible asset $94.6 million, impairment of other intangible assets $2.5 million, other-than-temporary impairment of available-for-sale securities $58.0 million, and tax effect of adjustments: b Acquisitions and integration activities: Integration and transaction related costs in respect of the acquisition of Jerini $10.3 million, IPR&D in respect of METAZYM acquired from Zymenex A S $135.0 million, IPR&D in respect of the acquisition of Jerini $128.1 million, additional interest expense incurred on settlement of the TKT appraisal rights litigation $73.0 million, and tax effect of adjustments: c Divestments, re-organizations and discontinued operations: Costs associated with inventory write-down and other exit costs in respect of DYNEPO $48.8 million, R&D commitment in respect of DYNEPO $6.5 million, costs associated with the introduction of a new holding company $14.8 million, gains on the disposal of non-core assets $20.7 million, gain on disposal of minority equity investment $9.4 million, discontinued operations in respect of non-core Jerini operations $17.6 million and tax effect of adjustments: and d Depreciation: Depreciation of $77.2 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.
